Skip to main content
Caplight Logo









AirNexis Therapeutics

AirNexis Therapeutics

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://airnexis.com/

Last Round

Series A

Mar 9, 2026

Est. Valuation

$341.7M

Total Funding Raised

$200M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

AirNexis Therapeutics is a biotechnology company developing clinical-stage therapies for chronic obstructive pulmonary disease (COPD) and other pulmonary conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

COPDchronic obstructive pulmonary diseaseinhaled therapybiopharmaceuticalPDE3/4 inhibitorrespiratory medicineclinical-stage biotechdrug developmentbronchodilatorsmall-molecule drugpulmonologyin-licensingclinical trialslung disease treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AirNexis Therapeutics Comparables

Compare AirNexis Therapeutics with similar companies based on industry and business-model similarity.

AirNexis Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Merck & Co., Inc.
83%
AeroRx Therapeutics
82%
Aeriant Therapeutics AB
78%

AirNexis Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 9, 2026
Series AJan 9, 2026

AirNexis Therapeutics Investors

Notable investors and investment history

AirNexis Therapeutics investors
InvestorRounds
Longitude CapitalSeries A
Enavate SciencesSeries A
Life Sciences at Goldman Sachs AlternativesSeries A
OrbiMedSeries A
Frazier Life SciencesSeries A
SR OneSeries A
Goldman Sachs AlternativesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 3, 2026

    Grew 38% QoQ, from 8 to 11 employees.

  • Aug 21, 2026

    Monthly visitors increased 52% MoM.

AirNexis Therapeutics Filings

Explore SEC and related filing metadata, where available.

AirNexis Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AirNexis Therapeutics's valuation, stock price, and market status.

Is AirNexis Therapeutics a public or private company?

AirNexis Therapeutics is a private company.

What is the current stock price of AirNexis Therapeutics?

AirNexis Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is AirNexis Therapeutics worth (valuation)?

AirNexis Therapeutics's valuation is estimated at $341.7M based on funding round data.

Can I buy AirNexis Therapeutics stock?

AirNexis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AirNexis Therapeutics's last funding round?

AirNexis Therapeutics's most recent funding round was Series A on January 9, 2026.

Who are the main investors in AirNexis Therapeutics?

Key investors in AirNexis Therapeutics include Frazier Life Sciences.

Will AirNexis Therapeutics IPO soon?

No public IPO plans have been announced for AirNexis Therapeutics.

How can I track AirNexis Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AirNexis Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range11
Year Founded2026
Last FundingMar 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?